Aligos Therapeutics (NASDAQ:ALGS) shares rose 7.6% to $6.55 in premarket trading, with no specific company announcement identified in the supplied information as an immediate catalyst for the move.
The increase came as the broader U.S. equity market traded lower. Recent developments at the clinical-stage biotechnology company have included its second-quarter 2026 financial results and an update on enrollment in a Phase 2 study of pevifoscorvir sodium.
Aligos Reports Narrower Second-Quarter Loss
Aligos reported its second-quarter 2026 financial results in early August, recording a net loss that was narrower than analysts had expected, while earnings per share also came in above consensus estimates.
The company also confirmed that non-dilutive capital received through a Greater China licensing agreement covering pevifoscorvir sodium had increased its available financial resources.
The supplied information does not provide the specific second-quarter financial figures or the value of the licensing-related capital.
Phase 2 B-SUPREME Study Reaches Full Enrollment
Following its quarterly results, Aligos announced that it had completed enrollment in its Phase 2 B-SUPREME study.
The trial is evaluating pevifoscorvir sodium in patients with chronic hepatitis B virus infection.
Completion of enrollment represents an operational milestone for the study. Future clinical results and the development outcome of pevifoscorvir sodium remain subject to the trial data and subsequent development and regulatory processes.
Aligos Outperforms Broader U.S. Market Premarket
The rise in Aligos shares came as major U.S. equity benchmarks moved lower. The Nasdaq was down 0.6%, the S&P 500 declined 0.2% and the Dow was 0.1% lower, according to the supplied market data.
Without a specific company announcement identified as the catalyst, the reason for the 7.6% premarket move cannot be established from the available information.
Aligos shares remained below their 52-week high of $13.69. The difference between the current share price and the 52-week high does not indicate whether or to what extent the stock will recover, with future performance dependent on company-specific and broader market developments.
Aligos Therapeutics stock price
